Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard’s Board of...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021
September 01, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
August 04, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs New HAE collaboration with Pharming Group highlights broad potential for HSC gene therapy Multiple...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
July 01, 2021 01:00 ET | Orchard Therapeutics (Europe) Limited
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
June 29, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA Guidance obtained on design of OTL-203 global registrational trial for MPS-IH Enrollment goal...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
May 13, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany Update on OTL-200 U.S. BLA Filing Strategy for...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
May 11, 2021 06:00 ET | Orchard Therapeutics (Europe) Limited
100% overall survival and ≥95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy 50 total participants represent largest published...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
April 28, 2021 07:01 ET | Orchard Therapeutics (Europe) Limited
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders First peer-reviewed presentation from company’s work in transduction...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
March 02, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
$150M Strategic Financing Supports Execution into the First Half of 2023 OTL-203 Achieves Proof of Concept (POC) in MPS-I Hurler Syndrome (MPS-IH); Registrational Trial Planned to Initiate by...
Orchard-New-Logo-102419-v01-rgb.png
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
February 25, 2021 07:00 ET | Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...